Fibrosis is a complex process that follows an injury or inflammation, and depends on the interactions of many cells, molecules and different signaling pathways. Animal models are valuable means to examine the pathogenesis of fibrotic diseases, to identify potential therapeutic targets and develop novel therapies for various human diseases.
At Oncodesign Services, we offer and develop various preclinical models of fibrotic diseases (skin, lung, kidney…) for pharmacology studies. Here we show how we developed functional readout to test the efficacy against lung fibrosis using flexiVent® device. In particular, we developed a plethysmography and validated it using histology.
Based on the literature on the bleomycin model and human IPF, the most relevant parameters for lung fibrosis monitoring are tissue elastance, static compliance and work of breathing. Here we observed valuable insight on the impairments of lung function caused by bleomycin injury and subsequent lung fibrosis. They were strongly correlated with histological modifications, highlighting the coherence and complementarity between such readouts.
Discover INPACT: an integrated preclinical pharmacology service for inflammatory diseases
Since 1995, Oncodesign Services has built discovery and preclinical expertise in precision medicine that is available as contract (CRO) services to sponsors in the global biopharma industry. Our experience can help you translate your mechanism of action into a clinical drug.
INPACT PoC Inflammation is an integrated preclinical pharmacology package to speed your selected drug candidate to the clinic. It combines the following capabilities to support your therapeutic discovery and innovation programs:
- In vitro screening
- Ex vivo screening
- Early ADME
- In vivo DMPK
- Bioanalytical development
- In vivo validation
- Pharmaco-imaging
- Investigative safety
- GLP toxicology available through partners
Learn more about our inflammation capabilities and models ? Contact us!
